Programmed death-ligand 1 (PD-L1) is suggested to be a predictive biomarker in non-smallcell lung carcinoma (NSCLC). However, the differential expression of PD-L1 in primary lung tumor vs. synchronous metastases, especially brain metastasis (BM), remains unclear. This study assessed the concordance of PD-L1 expression on tumor cells and tumor infiltrating lymphocytes (TILs) and CD8 + TIL intensity between primary lung tumors and synchronous BMs from 24 NSCLC patients. PD-L1, CD3, and CD8 positivity was determined by immunohistochemistry (IHC). PD-L1 scoring was based on the proportion of tumor cells with membranous expression of PD-L1 and the cutoff values <1%, 1-49%, and ≥50%. CD3 and CD8 positivity in TILs was evaluated semi-quantitatively and the proportion of CD3 + /CD8 + TILs was determined. PD-L1 expression on tumor cells and TILs was evaluated in relation to CD3 + /CD8 + TIL proportions and the intensity of CD8 + TILs between the paired primary lung and BM tissues. In the primary lung tumors, PD-L1 positivity was observed in 25%, 37.5%, and 37.5% cases for the cutoff values <1%, 1-49%, and ≥50%, respectively. PD-L1 expression on tumor cells was strongly correlated between the paired primary lung and BM tissues, in all cutoff groups. However, PD-L1 expression on TILs and the proportion of CD3 + /CD8 + TILs were not strongly correlated in all three groups between the paired primary lung tumors and BMs. The intensity of CD8 + TILs was concordant in only 54.16% of the paired primary lung tumors and BMs. This study showed a high concordance of PD-L1 expression in neoplastic cells between primary NSCLC and synchronous BMs.
INTRODUCTION
Immunotherapy methods targeting the programmed death receptor 1 (PD-1) and/or programmed death ligand-1 (PD-L1) have become new and seemingly valid cancer treatment options. With the discovery of PD-1/PD-L1 receptors and its interaction between the tumor cell and the immune system, studies have shown how the tumor blocks the immune system and progresses using this receptor signaling. PD-L1 and PD-L2 are members of the B7 family.
There are negative regulatory molecules on the cell surface that inhibit T cell activation or prompt apoptosis. These decrease the T cell activation by binding to the PD-1 receptors. This is an important step for the immune response to prevent tissue damage caused by induced inflammation. However, in cancer cells, PD-L1 and PD-L2 suppress the T cell attack and provide an escape from the immune system. Therefore, the tumor cells can form an appropriate tumor microenvironment and continue proliferation. Many studies have shown the successful outcomes of PD-1 and PD-L1 targeting immunotherapies in non-small cell lung carcinomas (NSCLC), which is the most common cancer type in the world (1) (2) (3) (4) (5) (6) (7) . The study of Liu et al. report an increased survival rate with upregulated PD-L1 expression in neurons and gliomas in Glioblastoma Multiform patients (8) .
Tumor-infiltrating lymphocytes (TIL) as members of the tumor microenvironment, especially of T cells, is also considered to be biomarker that according to some studies may predict response to anti-PD1 treatment in metastatic NSCLC, but as CD8+/CD4+ TILs ratio (9) (10) (11) .
PD-L1 is a biomarker and PD-L1 score gives us estimation of its presence in the tumorous tissue. The expression of PD-L1 is a dynamic event and is mostly heterogeneous (12) Brain metastases (BM) is a very common phenomenon in NSCLC patients. In terms of metastatic interactions, however, the brain is different from the other organs due to having its own tumor microenvironment. This results in the necessity to approach the brain metastases with different and alternative therapy options. Moreover, in many cases the symptoms of the lung cancer emerge due to the brain metastases instead of the primary lung tumor and the BM acts as the alert for the disease, as even smaller brain lesions of 3-5 mm can cause symptoms where 6 cm lung tumors sometimes do not. Similarly, brain lesions are much more lifethreatening than lung lesions, as they may cause malfunctions in vital centers of the brain and suppress various metabolic functions (13, 14) .
The differential expression of PD-L1 in tumor microenvironment between the primary tumor in the lung and the concurrent metastatic site remains unclear, particularly so for the BM's. There are some studies but this is second with comprehensive data about PD-L1 status in tumor cells and their microenvironment in primary and metastatic tumor (9, 15 ) . On the other hand, in cases of brain metastases of NSCLC, complete or partial removal of metastatic lesions from the brain through classical surgery is much more common than removal of the primary tumor from the lungs. If there is metastases to a distant organ, there usually are also lesions in various lymph nodes, and removal of the primary tumor is not considered to be an effective treatment in such a case (16) . This creates a precarious situation where the lesions in the brain may have to be removed through surgery, while the primary lesion in the lung is not operated. Even when stereotactic radiosurgery is an option, some tumors are just too large to effectively manage through radiotherapy, and classical surgery becomes the only option. This is important, because due to all of these facts above, in many cases the tissue removed from the brain also acts as a biopsy material where various pathological surveys are conducted, including the determination of PD-1 or PD-L1 scoring. In this sense, the accuracy between the PD-1 and/or PD-L1 ratings of the primary lung tumor and the brain metastases are important in order to be able to correctly determine the suitability of the cancer case for immunotherapy treatments that target these specific markers for such cases (17) .
This study investigates whether there is concordance of PD-L1 status and TIL rates together with intensity of CD8 lymphocytes, between the synchronous primary NSCLC tumors and BM's.
MATERIALS AND METHODS
24 patients diagnosed with NSCLC primary tumors and accompanying synchronous brain metastases were selected. All brain metastatic tissue had been removed before neoadjuvant therapy . This allows the comparison of lung carcinomas and their native brain metastases in terms of PD-L1 expressions and TIL rates without them being influenced by the treatments.
The obtained resected tumor specimens off of the brain metastases and the biopsy materials from the primary lung tumors were stored as formalin fixed-paraffin embedded (FFPE) tissue samples.
A total of 48 FFPE tissue blocks were sectioned at 5 µm. The tonsil was used as the control tissue and percentage rates were given. IHC for CD3 and CD8 was performed using Ventana 
RESULTS
A total of 24 patients were included in the study group (13 cases from Cerrahpasa Medical Faculty, 6 cases from Marmara University Medical Faculty, 3 cases from Medipol University and 2 cases from Trakya University Medical Faculty). The majority of patients were male (83.3% were male (n=20) and 16.6% were female (n=4)). 13 patients were at the age of 65 or higher, while 11 were younger than 65. We analyzed 48 paired primary lung cancers and brain metastases from 24 cases. There were 18 adenocarcinomas, 2 squamous cell carcinomas, 1 adenosquamous carcinoma, 1 pleomorphic carcinoma, 1 large cell carcinoma and 1 combined large cell neuoroendocrine carcinoma included in this study. The majority of our specimens were resection materials (n = 40 , 83 %; lung = 16, brain = 24); however, some of the biopsies were included (n = 8, 17%; lung = 8 ). Lung biopsy or resection was performed before brain metastases in 15 cases.
Of the 24 patients, 18 of them had PD-L1(+) lung tumor expression while 6 had PD-L1(-), and 17 had PD-L1(+) brain metastases while 7 had PD-L1(-). These results were exactly similar in the TIL PD-L1 rates. These results and further distribution types of PD-L1 and TIL can be observed in Table 1 . Figures 1 to 3 
represent samples for different correlation levels between primary lung tumor and BM PD-L1 expressions.
As can be seen, of the 24 patients, 6 had a negative expression in their lung tumor cells, while both the poor and strong positive groups had 9 patients each. The results are almost the same for the BM expressions rate, with 7 negatives, 9 poor positives, and 8 strong positives. For the TIL's, though, while the negative PD-L1 expression rates were similar (with 6 negatives in both the lung and BM cells), poor positives were considerably higher compared to the strong positives, in both the lung and BM tumors (13 and 16 patients for lung and BM poor positives respectively, and 5 and 2 patients for lung and BM strong positives, respectively) ( Table 2 ).
The correlations between the PD-L1 expression rates of lung and BM tumor cells can be observed in Table 3 . As can be seen, 15 patients (62,5%) had PD-L1 positive in both their lung and BM tumor cells. Of those 15 patients, only 3 had negative PD-L1 expression in their brain metastases (%12,5 of the total, %20 of the PD-L1 positive lung tumor cell sub-group). Of particular interest is the 2 patients who had negative PD-L1 expression in their lung tumor cells, yet had PD-L1 (+) in their brain metastases. Meanwhile, 4 patients had negative PD-L1 expression in both their lung and BM tumor cells.
PD-L1 expressions of the TIL's of the patients were similarly analyzed, and the results can be observed in Table 4 . As evident, the results almost similar the tumor cell PD-L1 expression rates between lung and BM's TIL's.
Using these values, a plotline comparison table was prepared to visualize PD-L1 correlations between Lung and BM tumor cells, and lung and BM's TIL's ( Figure 4 ). As can be seen, Lung and BM TC PD-L1 expressions are almost entirely in parallel, while the BM expression is similar, but not quite parallel.
Finally, using all of the above data combined, the below figure ( Figure 5 ) was plotted, which displays the box plots of PD-L1 expressions of TC's and TIL's, and CD8 expressions of primary lung tumor and BM. While the results for TC and TIL PD-L1 expressions were almost in parallel (as can be seen from the average lines plotting towards the middle sections of the boxes, and comparing the box sizes), the CD8 expressions vary greatly between Lung and BM samples.
DISCUSSION
The PD-L1 expression rates of the tumor cells of both the lung and BM tumors are statistically comparable in our study, meaning that the concordance of PD-L1 expression in neoplastic cells between the primary NSCLC's and their corresponding BM's is very high. This result means that the evaluation of PD-L1 in either the primary lung tumor or the BM can be considered valid in the selection of anti PD-1/PD-L1 immunotherapy treatment patients.
The TIL PD-L1 expressions were also similar in ratios. This is of interesting note as the microenvironment of the brain is quite different from the lung itself, but the TIL PD-L1 expression rates do not seem to be influenced by this fact.
On the other hand, when CD8 lymphocyte intensity among the TIL cells was compared between primary tumors and BM's, only 54.16% (13/24) of the tumor pairs were found to be compatible. Due to this low compatibility of CD8 intensity in TIL cells, this property cannot be considered applicable as a therapeutic target to use for primary and BM tumors.
Malpighi et al. has made a similar study in the literature and the results of this study are different with ours (9) . In this study, the researchers report significant changes in the classifications as many brain metastases lacked either PD-L1 expression, TIL, or both, even when they were present in the primary lung cancer samples (p=0.009). Though as a difference these researchers also considered spatial and temporal dimensions of the PD-L1 expression phenomena, this does not seem to be the cause of the difference between the results of the studies. The difference might be caused by the factor of patient race, or the fact that these researches relied more on biopsies rather than complete resections, or the fact that there was some time between the initial diagnosis of the lung tumor and brain metastases for some of the patients (different patient groups). It is also possible that the results vary due to different cut off points set, or PD-L1 antibodies used. They used the PD-L1 clone E1L3N in their studies and accepted > 5% PDL1 expression on tumor cells as positive.
There are other studies which are similar in nature, like the study of Berghoff et al which evaluates the PD-L1 expressions and TIL in BM's of small cell lung cancer (10) . An interesting point of comparison with this study is that while they report a 75% PD-L1 expression in brain metastases cells, they report only a 25% PD-L1 expression in TIL's. Another study of Berghoff et al also report a clear topographical and statistical correlation of TIL infiltration with PD-L1 expression in patients with melanoma and brain metastases (18) . While not directly comparable, the findings of these two studies are in line with ours.
Our study show that NSCLC BM harbor an active immune microenvirement with presence of TIL and expression on PD-L1.
The small number of cases, as well as the unequal distribution of histological subtypes of NSCLC, can be considered as limitations of our study.
Further research on this subject is required to gain deeper insight into the mechanism/biology of CD8 lymphocytes intensity in TIL cells and PD-L1 expression in NSCLC.
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